La vendita allo scoperto per Defiance Hotel, Airline, and Cruise ETF dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Defiance Hotel, Airline, and Cruise ETF. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Defiance Hotel, Airline, and Cruise ETF (ARCA:CRUZ), Report sulle vendite allo scoperto

Defiance Hotel, Airline, and Cruise ETF

Consumer Cyclical

Industrials

Real Estate

The Fund will generally use a replication strategy to achieve its investment objective, meaning the Fund will generally invest in all of the component securities of the Index in the same approximate proportions as in the Index. However, the Fund may use a representative sampling strategy, meaning it may invest in a sample of the securities in the Index whose risk, return, and other characteristics closely resemble the risk, return, and other characteristics of the Index as a whole, when the Funds sub-adviser believes it is in the best interests of the Fund (e.g., when replicating the Index involves practical difficulties or substantial costs, an Index constituent becomes temporarily illiquid, unavailable, or less liquid, or as a result of legal restrictions or limitations that apply to the Fund but not to the Index).

Hilton Worldwide Holdings, Inc.

Marriott International, Inc.

Royal Caribbean Cruises Ltd.

Delta Air Lines Inc.

Carnival Corp.

Ryanair Holdings Plc

Intercontinental Hotels Group Plc, Adr

United Airlines Holdings Inc.

Southwest Airlines Co.

Host Hotels & Resorts Inc.

International Consolidated Airlines Group Sa

H World Group Limited

Defiance Hotel Airline and Cruise ETF

Nanortalik,,Greenland,-,27,August,2024:,Close,Up,View,Of

Equities

Mid Cap

News

Movers

CRUZ

NCLH

SAEF

Strategie in evoluzione nel settore crocieristico: cessioni e nuovi accordi. Come cambia il futuro della compagnia e il mercato.

Norwegian Cruise Line: 4 navi lasciano la flotta, ma l&#39;espansione continua

CRUZ BATTERY METALS NEW by Cruz Battery Metals Corp.

Cruz Battery Metals Corp

JP Morgan analyst Jimmy Bhullar maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Neutral and raises the price target from $125 to $129.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on The Hartford Insurance Gr, Raises Price Target to $129

<a href="https://www.finance.senate.gov/hearings/the-presidents-2025-trade-policy-agenda" title="https://www.finance.senate.gov/hearings/the-presidents-2025-trade-policy-agenda">https://www.finance.senate.gov/hearings/the-presidents-2025-trade-policy-agenda</a>

Macro Economic Events

Politics

Global

Economics

General

U.S. Trade Representative Jamieson Greer Says We Are Trying To Limit Imports Driven By Unfair Trade Practices While Promoting U.S. Exports; There Is No Particular Timeline On Trump's Negotiations With Other Countries On Tariffs; We Are Trying To Work Very Quickly On Trade Negotiations; Vietnam Understands That It Is A Major Target Of Trump Tariff Action; Trump Has Been Clear That He Won't Do Tariff Exemptions In The Near Term

Truist Securities analyst Jamie Cook maintains Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) with a Hold and lowers the price target from $141 to $130.

Truist Securities Maintains Hold on Jacobs Solutions, Lowers Price Target to $130

Truist Securities analyst Jamie Cook maintains Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Buy and lowers the price target from $398 to $324.

Truist Securities Maintains Buy on Quanta Services, Lowers Price Target to $324

JP Morgan analyst Pablo Singzon maintains Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) with a Neutral and lowers the price target from $11 to $10.

HGTY

JP Morgan Maintains Neutral on Hagerty, Lowers Price Target to $10

Shares of space exploration company Intuitive Machines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) are <a href="https://www.benzinga.com/movers">trading higher on Tuesday</a>, after the company said it will launch its fourth mission to the Moon using a SpaceX Falcon 9 rocket. 
The upcoming lunar delivery,<a href="https://www.benzinga.com/pressreleases/25/04/g44683192/intuitive-machines-selects-spacex-to-launch-its-fourth-lunar-lander-mission-and-lunar-data-relay-s"> dubbed IM-4, will lift off from Florida</a> and is scheduled to carry a suite of communication assets and scientific instruments as part of its partnership with NASA.
The IM-4 mission contributes to Intuitive Machines&#8217; continued efforts supporting NASA's Near Space Network Services (NSNS) program. 
Also Read: <a href="https://www.benzinga.com/25/04/44671636/nvidia-applied-materials-provide-115m-fund-to-digital-engineering-startup-rescale">Nvidia, Applied Materials Back Digital Engineering Startup In $115M Round</a>
Through the NSNS contract awards, Intuitive Machines has been tasked with developing both direct-to-Earth (DTE) transmission capabilities and a lunar satellite relay network. 
Scheduled for liftoff in 2027, the mission will deploy a pair of lunar relay satellites to strengthen communication systems for future Artemis operations.
&#8220;Lunar surface delivery and data relay satellites are central to our strategy to commercialize the Moon,&#8221; said CEO Steve Altemus.
As part of the Commercial Lunar Payload Services (CLPS) program, IM-4 will deliver six NASA-backed payloads to the Moon's surface. 
These include scientific instruments to explore the Moon's south pole region, notably a European Space Agency-led drilling system intended to search for subsurface water.
In 2024, Intuitive Machines successfully landed on the Moon with its Nova-C lander. This marked the first U.S. lunar landing since 1972. 
The company followed up with a second mission to the Moon's south pole in 2025. During the second mission, the company&#8217;s <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44195423/whats-going-on-with-intuitive-machines-shares-friday">IM-2 lunar lander Athena faced technical challenges</a> during its moon landing.
The Athena landed on its side 250 meters away from its intended site. This <a href="https://www.benzinga.com/general/space/25/03/44181829/intuitive-machines-stock-is-in-free-fall-thursday-whats-going-on">created issues with power generation</a> and measurements from the laser range finders.
Intuitive Machines&#8217; <a href="https://www.benzinga.com/news/earnings/25/03/44457781/intuitive-machines-stock-is-moving-higher-monday-whats-going-on-2">fourth-quarter revenue jumped 79%</a> to $54.66 million and the company expects 2025 revenue to be in the range of $250 million to $300 million versus estimates of $342.47 million.
Price Action: LUNR shares traded higher by 10.5% at $7.87 at last check on Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/44671105/cloudflare-acquires-outerbase-to-streamline-ai-app-development-our-goal-is-to-make-it-easy-and-accessible-for-any-developer">Cloudflare Acquires Outerbase To Streamline AI App Development, &#8216;Our Goal Is To Make It Easy And Accessible For Any Developer&#8217;</a></li>
</ul>
Image: Shutterstock

SPACE

LUNR

Intuitive Machines Taps SpaceX For 2027 Lunar Mission, Stock Gains

<a href="https://register.epo.org/application?number=EP19173234" title="https://register.epo.org/application?number=EP19173234">https://register.epo.org/application?number=EP19173234</a>

Biotech

VERO

Venus Concept Has Received A Decision To Grant European Patent Number EP3542745 Titled "DEVICE FOR FRACTIONAL RF TREATMENT OF THE SKIN (TO IMPROVE APPEARANCE)"

Truist Securities analyst Jamie Cook maintains Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) with a Buy and lowers the price target from $58 to $47.

Truist Securities Maintains Buy on Terex, Lowers Price Target to $47

Trading Ideas

FATN

FatPipe Shares Halted On Circuit Breaker To The Upside

Truist Securities analyst Jamie Cook maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Hold and lowers the price target from $118 to $94.

Truist Securities Maintains Hold on Oshkosh, Lowers Price Target to $94

IPOs

FatPipe IPO Opens For Trade At $6.50/Share; IPO Priced At $5.75/Share

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) on Monday settled its litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals Laboratories, Inc. related to patents for Exparel (bupivacaine <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">liposome injectable suspension)</a>.
Exparel is Pacira BioSciences' non-opioid analgesic pain management and is indicated for postsurgical analgesia.
As part of the settlement, the parties will file Consent Judgments with the United States Court of Appeals for the Federal Circuit and the United States District Courts for the District of New Jersey and the Northern District of Illinois that enjoin Fresenius from marketing generic bupivacaine liposome injectable suspension before the expiration of the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44674361/pacira-biosciences-announces-settlement-of-u-s-patent-litigation-for-exparel" rel="noreferrer noopener">patents-in-suit</a>.
In settlement of all outstanding claims in the litigations, Pacira has agreed to provide Fresenius with a license to Pacira&#8217;s patents required to manufacture and sell certain volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date that is sometime in early 2030.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42854744/pacira-biosciences-secures-fda-approval-for-new-iovera-smarttip-to-manage-chronic-low-back-pain" rel="noreferrer noopener">Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain</a>
The license will permit generic bupivacaine liposome injectable suspension entry before the July 2, 2044, expiration date of the last-to-expire of Pacira&#8217;s Orange Book-listed patents for Exparel.
While the agreed-upon volume-limited percentages are confidential, they begin at a high-single-digit percentage of the total volumes distributed in the U.S. market and increase gradually in each 12-month period following the volume-limited entry date until reaching a percentage in the low thirties in 2033 and increasing modestly in each of the next two 12-month periods before reaching a maximum percentage in the high thirties of the total volumes distributed in the U.S. for the final three years of the agreement.
In addition, Pacira has agreed to provide Fresenius with a license to Pacira&#8217;s patents required to manufacture and sell an unlimited quantity of generic bupivacaine liposome injectable suspension in the U.S. beginning no earlier than 2039.
In an SEC <a href="https://www.benzinga.com/secfilings/25/04/44674982/pacira-biosciences-inc-general-corporate-statement-form8" target="_blank" rel="noreferrer noopener">filing</a>, the company&#8217;s expected savings concerning, among other things, the avoidance of the fees, costs, time and resources associated with continuing the Litigations, the company will pay the Fresenius Parties $7.0 million.
Exparel net product sales were $147.7 million in the fourth quarter of 2024, a 3% <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44024616/pacira-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">year over year increase</a>.
In August 2024, Pacira BioSciences announced that the U.S. District Court for the District of New Jersey found that the company's U.S. Patent No. 11,033,495 (the ‘495 patent)&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40321378/pain-management-focused-pacira-biosciences-loses-patent-fight-for-key-drug-jp-morga" rel="noreferrer noopener">is not valid</a>.
In November 2021, Pacira BioSciences&nbsp;<a target="_blank" href="https://investor.pacira.com/news-releases/news-release-details/pacira-files-lawsuit-against-evenus-patent-infringement?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">filed</a>&nbsp;a lawsuit in the United States District Court for the District of New Jersey against&nbsp;eVenus Pharmaceutical Laboratories for patent infringement of U.S. Patent Number 11,033,495.
Analyst Reaction:
<ul>
<li>HC Wainwright maintains Pacira BioSciences with a Buy, raising the price target <a href="https://www.benzinga.com/quote/PCRX/analyst-ratings" target="_blank" rel="noreferrer noopener">from $48 to $65</a>.</li>
<li>Needham reiterates Pacira BioSciences with a Buy and maintains a price target of $32.</li>
</ul>
Price Action: PCRX stock is up 16.8% at $26.77 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44685591/walgreens-boots-alliance-q2-earnings-beats-expectations-suspends-guidance-amid-pending-private-equity-deal-with-sycamore-partners" target="_blank" rel="noreferrer noopener">Walgreens Boots Alliance Q2 Profit Falls 47.5%, Suspends Guidance On Pending Private Equity Deal</a></li>
</ul>
Photo: Shutterstock

Health Care

Legal

PCRX

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

Mark Cuban doesn't throw around financial panic lightly—but over the weekend, the billionaire entrepreneur and <a href="https://www.benzinga.com/personal-finance/25/02/43435413/mark-cubans-cost-plus-marketplace-now-sells-over-6000-medicines-saving-customers-between-40-60-by-cutting-out-the-middle-man">Cost Plus Drugs co-founder</a> lit up Bluesky with a warning that's hard to ignore.&nbsp;
In his view, the latest combination of sweeping tariffs and deep government cuts could send the U.S. economy spiraling into a crisis even worse than 2008.
"If the new tariffs stay in place for multiple years, and are enforced and inflationary, and DOGE continues to cut and fire, we will be in a far worse situation than 2008," <a href="https://bsky.app/profile/mcuban.bsky.social/post/3lm3z4inx6c2b">Cuban posted on Saturday</a>, responding to a user who asked him about the "worst case" economic impact of Trump's tariff plan.
Don't Miss:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
For those who forgot—or maybe just blocked it out—2008 wasn't just a bad year. It was the year the financial system cracked. Banks collapsed. Millions lost homes, jobs, and retirement savings. The stock market tanked, credit dried up, and the government had to step in with massive bailouts just to keep the economy breathing. It was the worst financial crisis since the Great Depression.
And Cuban's not being dramatic—he's drawing direct parallels.
This <a href="https://www.benzinga.com/markets/equities/25/04/44642355/trumps-25-auto-tariffs-spark-stellantis-layoffs-gm-expansion-uaws-shawn-fain-calls-job-cuts-completely-unnecessary">latest round of tariffs</a>, announced by the Trump administration last Wednesday, marks a sharp escalation in trade restrictions. They're aimed at foreign imports but could hit American consumers in the wallet, fast. Add to that the Domestic Office of Government Efficiency pushing aggressive federal workforce reductions, and Cuban sees a dangerous storm forming.
Trending: <a href="https://www.benzinga.com/money/arrived-private-credit-fund">Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom</a>
Though he didn't go into detail on DOGE's connection to the economy, there's already been fallout. Among the targeted agencies? The Consumer Financial Protection Bureau and the IRS's tax evasion enforcement arm—two departments that help regulate bad behavior and secure government revenue. Cutting those could mean less consumer protection and more unpaid taxes.
Cuban did offer a <a href="https://bsky.app/profile/mcuban.bsky.social/post/3lm4meuumzc2n">glimpse at a "best case" scenario</a> when asked what could cool things off:
"Best case he turns off Apr 2nd tariffs Monday. Leaves the 10pct tariffs (not great, but realistic). <a href="https://www.benzinga.com/news/25/03/44575557/mark-cuban-says-if-they-replaced-elon-musk-with-him-hes-still-try-to-make-government-smaller-by-cutting-a-lot-of-people">Elon leaves Doge</a>, which decides to stagger the cuts over 3 yrs, accounting for local impact. That slows the economy, reducing interest rates, reducing payments on debt to affordable levels."
In other words, scale it back. Or at least, don't yank the rug all at once.
But Cuban's bottom line is clear: this isn't just about political strategy—it's about economic survival.
And if his predictions are right, the price of inaction might be a lot more than higher grocery bills.
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a></li>
</ul>

Personal Finance

Mark Cuban Says Brace For A 'Far Worse Than 2008' Financial Crisis If The New Tariffs Stick Around and DOGE Continues Cutting and Firing

Truist Securities analyst Jamie Cook maintains AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with a Buy and lowers the price target from $125 to $105.

AGCO

Truist Securities Maintains Buy on AGCO, Lowers Price Target to $105

WIIM

Wells Fargo shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and announced a price target of $77.

Truist Securities analyst Jamie Cook maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Buy and lowers the price target from $17 to $16.

Truist Securities Maintains Buy on CNH Industrial, Lowers Price Target to $16

RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) shares are trading lower after the <a href="https://www.benzinga.com/pressreleases/25/04/b44680994/rpm-reports-fiscal-2025-third-quarter-results" target="_blank" rel="noreferrer noopener">company reported fiscal third-quarter results</a>.
Sales declined 3% year over year to $1.48 billion, missing the consensus of $1.51 billion.
Sales decreased due to weak demand from specialty OEM manufacturing end markets and unfavorable weather conditions.
Geographically, sales decreased in North America, while Latin America and Asia / Pacific&nbsp;declined.
Adjusted EPS was&nbsp;$0.35,&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missing the consensus of&nbsp;$0.49.</a>
Adjusted EBIT fell 29% to $78.2 million due to reduced production volumes, adverse foreign currency impacts, and temporary costs related to MAP 2025 plant consolidations and start-up activities.
For the nine months ended Feb. 28, operating cash flow was $619.0 million, supported by MAP 2025-driven efficiency.
Total debt decreased to&nbsp;$2.10 billion&nbsp;from&nbsp;$2.19 billion, driven by the reduction of $0.09 billion on improved cash flow to repay higher-cost debt.
Capital expenditures rose to&nbsp;$158.9&nbsp;million from $138.1&nbsp;million a year ago, driven by investments in shared RPM centers, a new production facility in India, and MAP 2025-enabled plant consolidations.
The company returned&nbsp;$242.6&nbsp;million&nbsp;to stockholders via dividends and buybacks.
Frank C. Sullivan, RPM chairman and CEO said, &#8221;Unseasonably cold weather in the southern U.S. and wildfires in the west reduced demand in geographies that typically have more construction and outdoor project activity in winter months.&#8221;
&#8220;As we look toward the fourth quarter, macroeconomic conditions are challenging, but we are seeing pockets of positive momentum and are leveraging our focus on repair and maintenance in both construction and consumer end markets. As demonstrated in prior economic cycles, the ability of our products and services to extend asset life becomes even more attractive to end users when budgets are tight.&#8221;
&#8221;Additionally, RPM associates continue to implement initiatives to outgrow our markets, including new product introductions, and achieve efficiency improvements. We anticipate that this will result in modest earnings growth in the fourth quarter with the financial benefits of MAP 2025 becoming even more evident when sustained volume growth returns.&#8221;
&#8220;While the tariff situation is dynamic, most of our businesses have limited cross-border trade for raw material procurement and finished good sales. This helps mitigate the effects of tariffs; however, we are not immune, and we assume that raw material inflation will increase from low-single-digits to mid-single digits as a result of currently known tariffs,&#8221;
Outlook:&nbsp;For the&nbsp;fourth quarter, RPM&nbsp;expects consolidated sales to remain flat <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">compared to prior-year records</a>.
In particular, CPG sales is expected to remain flat Y/Y, PCG sales to increase in the mid-single-digit percentage range and SPG and Consumer Group sales to decline in the low-single-digit percentage range.
In the quarter, the company expects adjusted EBIT to be up in the low-single-digit percentage range Y/Y.
Investors can gain exposure to the stock via&nbsp;Invesco Dorsey Wright Basic Materials Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYZ#NASDAQ">PYZ</a>) and Invesco S&amp;P MidCap Quality ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XMHQ#NYSE">XMHQ</a>).
Price Action: RPM shares are down 4.38% at $102.02 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44679853/wall-street-eyes-recovery-as-sp-500-nasdaq-futures-rise-after-trumps-tariff-driven-selloff-wipes-out-9-trillion-in-six-weeks" target="_blank" rel="noreferrer noopener">Wall Street Eyes Recovery As S&amp;P 500, Nasdaq Futures Rise After Trump&#8217;s Tariff-Driven Selloff Wipes Out $9 Trillion In Six Weeks</a></li>
</ul>
Photo: Shutterstock/PJ McDonnell

Earnings

Large Cap

Guidance

PowerShares Dynamic Basic Materials Sector Portfolio

XMHQ

RPM Q3: Weather, Foreign Currency, and Lower Demand Weigh on Performance, Guidance Sees Modest Growth Ahead

U.S. Trade Representative Jamieson Greer Says Reciprocal Tariffs Are Generally Lower In The Western Hemisphere

Truist Securities analyst Jamie Cook maintains United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) with a Buy and lowers the price target from $956 to $732.

Truist Securities Maintains Buy on United Rentals, Lowers Price Target to $732

Keybanc analyst John Vinh maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Overweight and lowers the price target from $60 to $55.

Comments

Defiance Hotel, Airline, and Cruise ETF

Vendite allo scoperto

Defiance Hotel, Airline, and Cruise ETF (ARCA:CRUZ), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO